, an analyst from TD Cowen, maintained the Buy rating on WELL Health Technologies Corp. The associated price target is C$7.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
analyst has given his Buy rating due to a combination of factors, including WELL’s sustained outperformance in its core Canadian operations and its strong positioning to capitalize on structural changes in the national health care system. The company is delivering solid organic growth, enhancing margins, and maintaining robust F2026 revenue and EBITDA guidance, which supports confidence in its medium- to long-term financial trajectory.
Additionally, WELL is progressing on strategic initiatives such as potential U.S. asset divestitures and the anticipated WELLSTAR IPO, which could unlock shareholder value and streamline the portfolio. The rollout of its WELL Health Intelligence Platform and a planned cost-optimization program are expected to further boost efficiency and margins, while a healthy M&A pipeline in Canadian clinics provides visibility into continued expansion and revenue growth.
In another report released today, ATB Cormark Capital Markets also maintained a Buy rating on the stock with a C$5.00 price target.